Aegera Therapeutics Inc. raised C$17 million (US$10.7 million) in a private round of financing, which it will use to move its XIAP antisense program into Phase I trials in cancer next year. (BioWorld Today)

Aegera Therapeutics Inc. raised C$17 million (US$10.7 million) in a private round of financing, which it will use to move its XIAP antisense program into Phase I trials in cancer next year. (BioWorld Today)